Cartalax

Name:  Lynn
Wechat：  15914422644

Tel：+86  15914422644

Whatsapp: +852 6252 8290

Email：    guangsheng 5   @zgguangsheng.com

1. Core Molecular & Physicochemical Specifications

2. Mechanism of Action

1. Chondrocyte Activation: Stimulates chondrocyte proliferation and matrix synthesis, promoting repair of damaged articular cartilage and restoring extracellular matrix (ECM) integrity.
2. Collagen & Proteoglycan Synthesis: Enhances type II collagen and aggrecan production, critical for cartilage elasticity, load-bearing capacity, and joint mobility.
3. Anti-Inflammatory Modulation: Reduces synovial inflammation by inhibiting pro-inflammatory cytokines (e.g., IL-1β, TNF-α), alleviating pain and stiffness in degenerative joint conditions.

3. Biological Functions & Research Applications

3.1 Core Biological Effects

• Cartilage Regeneration: Accelerates ECM repair in osteoarthritis models, reducing cartilage erosion and improving joint function.
• Joint Inflammation Reduction: Mitigates synovitis, relieving pain and improving mobility in preclinical joint injury models.
• Collagen Type II Enhancement: Boosts synthesis of cartilage-specific collagen, supporting long-term joint structural integrity.

3.2 Research Applications

3. Production & Quality Control

3.1 Manufacturing Process

1. Solid-Phase Peptide Synthesis (SPPS): Precisely assembles the AED sequence; purified via reverse-phase HPLC (RP-HPLC) to ≥98% purity.
2. Lyophilization: Freeze-drying produces stable powder with extended shelf life; vacuum-sealed for storage.
3. Batch Testing: Each lot undergoes HPLC purity, amino acid composition, and endotoxin screening before release.

3.2 Quality Testing Standards

4. Administration, Safety & Regulatory Status

4.1 Administration Routes (Research Use Only)

• Intra-Articular Injection: Direct delivery to joint space (preferred for localized cartilage effects).
• Subcutaneous Injection: Systemic delivery for broader joint health studies.
• In Vitro Application: Added to cell culture media to study chondrocyte behavior.

4.2 Safety Profile (Preclinical Data)

• Toxicity: Low acute toxicity; no organ-specific toxicity reported in rodent studies at research doses.
• Adverse Effects: Mild local irritation at injection sites (rare); no systemic inflammatory or allergic reactions observed.
• Contraindications (Research): Hypersensitivity to peptide components; use in pregnant/lactating animals only with ethical approval.

4.3 Regulatory Status

• Classification: Research Use Only (RUO); not approved for human clinical use by FDA, EMA, or NMPA.
• Global Availability: Sourced from peptide manufacturers (e.g., Ningbo Inno Pharmchem, Typeptide Biotech) for preclinical and research applications.

5. Key Advantages & Limitations

5.1 Advantages

1. Targeted Joint Repair: Directly stimulates chondrocytes without off-target systemic effects.
2. Synergistic Potential: Combinable with other joint therapeutics (e.g., glucosamine, hyaluronic acid) for enhanced efficacy.
3. High Purity & Stability: Manufactured to strict quality standards, ensuring consistent research results.

5.2 Limitations

1. Preclinical Stage: Limited human clinical data; long-term safety and efficacy unestablished.
2. Delivery Challenges: Requires injection for localized effects; oral bioavailability unproven.
3. Regulatory Barriers: Not approved for human use; restricted to research settings.